← 產業報告目錄
Cell and Gene Therapy Manufacturing Quality Control (QC) Market Size, Share & Trends Analysis Report By Component (Equipment & Accessories, Consumables, Others), By Application (Sterility Testing, Purity Testing, Potency Testing, Identity Testing, Others (stability, viability, etc.)), By Process (Upstream Processing, Downstream Processing, Packaging), By End-User (Pharmaceutical & Biotechnology Companies, Contract Manufacturing Organizations), By Region, And By Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-02頁數 179報告編號 INSIGHTACE-39902a66a5
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Valued at USD 2.71 Bn as of 2024, the global Cell and Gene Therapy Manufacturing Quality Control (QC) Market is expected to climb to USD 16.32 Bn by 2034, reflecting a compound annual growth rate of 19.8% over the 2025–2034 period.
The Cell and Gene Therapy Manufacturing Quality Control (QC) sector involves dynamics.
The market's upward path is fueled by mounting healthcare spending, technological evolution, and the mounting focus on personalized and precision-based approaches in healthcare.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, fueled by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cell and Gene Therapy Manufacturing Quality Control (QC) Market Snapshot
Chapter 4. Global Cell and Gene Therapy Manufacturing Quality Control (QC) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Component Estimates & Trend Analysis
5.1. by Component & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Component:
5.2.1. Equipment & Accessories
5.2.2. Consumables
5.2.3. Others
Chapter 6. Market Segmentation 2: by Analytical Method Estimates & Trend Analysis
6.1. by Analytical Method & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Analytical Method:
6.2.1. Sterility Testing
6.2.2. Purity Testing
6.2.3. Potency Testing
6.2.4. Identity Testing
6.2.5. Others (Stability, Viability, Etc.)
Chapter 7. Market Segmentation 3: by Process Estimates & Trend Analysis
7.1. by Process & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Process:
7.2.1. Upstream Processes
7.2.2. Downstream Processes
7.2.3. Process Development
Chapter 8. Market Segmentation 4: by End-User Estimates & Trend Analysis
8.1. by End-User & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End-User:
8.2.1. Pharmaceutical & Biotechnology Companies
8.2.2. Contract Manufacturing Organizations
Chapter 9. Cell and Gene Therapy Manufacturing Quality Control (QC) Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by Component, 2021-2034
9.1.2. North America Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by Analytical Method, 2021-2034
9.1.3. North America Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by Process, 2021-2034
9.1.4. North America Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
9.1.5. North America Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.2. Europe
9.2.1. Europe Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by Component, 2021-2034
9.2.2. Europe Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by Analytical Method, 2021-2034
9.2.3. Europe Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by Process, 2021-2034
9.2.4. Europe Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
9.2.5. Europe Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.3. Asia Pacific
9.3.1. Asia Pacific Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by Component, 2021-2034
9.3.2. Asia Pacific Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by Analytical Method, 2021-2034
9.3.3. Asia-Pacific Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by Process, 2021-2034
9.3.4. Asia Pacific Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
9.3.5. Asia Pacific Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.4. Latin America
9.4.1. Latin America Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by Component, 2021-2034
9.4.2. Latin America Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by Analytical Method, 2021-2034
9.4.3. Latin America Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by Process, 2021-2034
9.4.4. Latin America Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
9.4.5. Latin America Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.5. Middle East & Africa
9.5.1. Middle East & Africa Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by Component, 2021-2034
9.5.2. Middle East & Africa Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by Analytical Method, 2021-2034
9.5.3. Middle East & Africa Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by Process, 2021-2034
9.5.4. Middle East & Africa Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
9.5.5. Middle East & Africa Cell and Gene Therapy Manufacturing Quality Control (QC) Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. bioMérieux SA
10.2.2. Bio-Rad Laboratories, Inc.
10.2.3. Bio-Techne Corporation
10.2.4. QIAGEN
10.2.5. Charles River Laboratories International, Inc.
10.2.6. Lonza Group AG
10.2.7. Merck KGaA
10.2.8. Intertek Group plc
10.2.9. Thermo Fisher Scientific, Inc.
10.2.10. Eurofins Scientific S.E.
10.2.11. F. Hoffmann-La Roche Ltd.
10.2.12. Catalent
10.2.13. Wuxi AppTec
10.2.14. Takara Bio Inc
10.2.15. Oxford Biomedica plc
10.2.16. Cell and Gene Therapy Catapult
10.2.17. FUJIFILM Holdings Corporation
10.2.18. Danaher (Cytiva)
10.2.19. Sartorius AG
10.2.20. AGC Biologics.
10.2.21. Eurofins Scientific
10.2.22. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們